Skip to main content

Advertisement

SpringerLink
Log in

Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Background

The association between HRQL measures with outcomes in patients with metastatic hormone-refractory prostate cancer (HRPC) is unclear.

Methods

Baseline and 12-week HRQL was collected using the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy – Prostate (FACT-P). Outcomes included: (1) survival; (2) time to disease progression and (3) time to bone pain. Cox proportional hazards regression models were used. The relative predictive performance of each HRQL instrument and domain was compared.

Results

Baseline HRQL scores and 12-week change scores > the median were significant predictors of all clinical outcomes but varied by domain. For example, the hazard of death for a change in FACT-P Grand Total Score > median was 49% of the hazard for a change ≤ the median. Including baseline or 12-week change in HRQL resulted in improvement in prediction performance.

Conclusions

Patients with better baseline HRQL have better predicted survival, time to disease progression and pain prognosis than those with worse HRQL. In addition, the 12-week change in HRQL appears to improve predictive accuracy for most clinical outcomes. It appears that greater deterioration in HRQL is prognostic for rapid disease progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. American Cancer Society. Available at: http://www.cancer.org/downloads/stt/Leading_Sites_of_New_Cancer_Cases_and_Deaths___2005_Estimates.pdf. Accessed December 24, 2005

  2. Canadian Cancer Society. Available at: http://www.bc.cancer.ca/ccs/internet/standard/ 0,3182,3172_14279_langId-en,00.html. Accessed December 24, 2005

  3. Boyle P, Ferlay J. (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16(3):481–488

    Article  PubMed  CAS  Google Scholar 

  4. U.K. National Statistics. Available at: http://www.statistics.gov.uk/statbase/Product.asp?vlnk = 14209. Accessed December 24, 2005

  5. Australian Institute of Health and Welfare. Available at: http://www.aihw.gov.au/publications/can/ca01/ca01-c03.pdf. Accessed December 24, 2005

  6. Petrylak DP, Tangen CM, Hussain MH, et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15):1513–1520

    Article  PubMed  CAS  Google Scholar 

  7. Tannock IF, de Wit R, Berry WR, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512

    Article  PubMed  CAS  Google Scholar 

  8. Sommers SD, Ramsey SD (1999) A review of quality-of-life evaluations in prostate cancer. Pharmacoeconomics. 16(2):127–140

    Article  PubMed  CAS  Google Scholar 

  9. Schellhammer P, Cockett A, Boccon-Gibod L, et al. (1997) Assessment of endpoints for clinical trials for localized prostate cancer. Urology 49(4A Suppl):27–38

    Article  PubMed  CAS  Google Scholar 

  10. Dancey J, Zee B, Osoba D, et al. (1997) Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. Quality of Life Research 6(2):151–158

    Article  PubMed  CAS  Google Scholar 

  11. Vigano A, Donaldson N, Higginson IJ, Bruera E, Mahmud S, Suarez-Almazor M (2004) Quality of life and survival prediction in terminal cancer patients: a multicenter study. Cancer 101(5):1090–1098

    Article  PubMed  Google Scholar 

  12. Coates A, Porzsolt F, Osoba D. (1997) Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 33(7):1025–1030

    Article  PubMed  CAS  Google Scholar 

  13. Loprinzi CL, Laurie JA, Wieand HS, et al. (1994) Prospective evaluation of prognostic variables from patient-completed questionnaires. J Clin Oncol 12(3):601–607

    PubMed  CAS  Google Scholar 

  14. Sloan JA, Loprinzi CL, Laurine JA, et al. (2001) A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol 19(15):3539–3546

    PubMed  CAS  Google Scholar 

  15. Shadbolt B, Barresi J, Craft P. (2002) Self-rated health as a predictor of survival among patients with advanced cancer. J Clin Oncol 20(10):2514–2519

    Article  PubMed  Google Scholar 

  16. Coates A, Gebski V, Signorini D, et al. (1992) Prognostic value of quality-of-life scores during chemotherapy for advanced breast-cancer. J Clin Oncol 10(12):1833–1838

    PubMed  CAS  Google Scholar 

  17. Butow PN, Coates AS, Dunn SM (2000) Psychosocial predictors of survival: metastatic breast cancer. Ann Oncol 11(4):469–474

    Article  PubMed  CAS  Google Scholar 

  18. Shimozuma K, Sonoo H, Ichihara K, Tanaka K (2000) The prognostic value of quality-of-life scores: preliminary results of an analysis of patients with breast cancer. Surg Today 30(3):255–261

    Article  PubMed  CAS  Google Scholar 

  19. Coates AS, Hurny C, Peterson HF, et al. (2000) Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol 18(22):3768–3774

    PubMed  CAS  Google Scholar 

  20. Earlam S, Glover C, Fordy C, Burke D, AllenMersh TG (1996) Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol 14(1):171–175

    PubMed  CAS  Google Scholar 

  21. Blazeby JM, Brookes ST, Alderson D (2001) The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut 49(2):227–230

    Article  PubMed  CAS  Google Scholar 

  22. Coates A, Thomson D, McLeod GRM, et al. (1993) Prognostic value of quality-of-life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant-melanoma. Eur J Cancer 29A(12):1731–1734

    Article  PubMed  CAS  Google Scholar 

  23. Butow PN, Coates AS, Dunn SM (1999) Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol 17(7):2256–2263

    PubMed  CAS  Google Scholar 

  24. Buccheri GF, Ferrigno D, Tamburini M, Brunelli C (1995) The patients perception of his own quality-of-life might have an adjunctive prognostic-significance in lung-cancer. Lung Cancer Mar 12(1–2):45–58

    Article  CAS  Google Scholar 

  25. Herndon JE, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J (1999) Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer 85(2):333–340

    Article  PubMed  Google Scholar 

  26. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (2001) Quality of life in lung cancer patients – as an important prognostic factor. Lung Cancer 31(2–3):233–240

    Article  PubMed  CAS  Google Scholar 

  27. Halabi S, Small EJ, Kantoff PW, et al. (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21(7):1232–1237

    Article  PubMed  Google Scholar 

  28. Cho D, Di Blasio CJ, Rhee AC, Kattan MW (2003) Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT). Urol Oncol. 21(4):282–291

    PubMed  CAS  Google Scholar 

  29. Collette L, van Andel G, Bottomley A, et al. (2004) Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol. 22(19):3877–3885

    Article  PubMed  Google Scholar 

  30. Curran D, Fossa S, Aaronson N, Kiebert G, Keuppens E, Hall R (1997) Baseline quality of life of patients with advanced prostate cancer. Eur J Cancer 33(11):1809–1814

    Article  PubMed  CAS  Google Scholar 

  31. Tannock IF, Osoba D, Stockler MR, et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14(6):1756–1764

    PubMed  CAS  Google Scholar 

  32. Moore MJ, Osoba D, Murphy K, et al. (1994) Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol. 12(4):689–694

    PubMed  CAS  Google Scholar 

  33. Herr HW, Kornblith AB, Ofman U (1993) A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 71(3 Suppl):1143–1150

    Article  PubMed  CAS  Google Scholar 

  34. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ (1997) Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50(6):920–928

    Article  PubMed  CAS  Google Scholar 

  35. Yount S, Cella D, Banik D, Ashraf T, Shevrin D (2003) Brief assessment of priority symptoms in hormone refractory prostate cancer: The FACT Advanced Prostate Symptom Index (FAPSI). Health Qual Life Outcomes 1(1):69

    Article  PubMed  Google Scholar 

  36. Harrell FE, Jr., Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 15(4):361–387

    Article  PubMed  Google Scholar 

  37. Anderson JR, Cain KC, Gelber RD (1983) Analysis of survival by tumor response. J Clin Oncol. 1(11):710–719

    PubMed  CAS  Google Scholar 

  38. Tamburini M, Brunelli C, Rosso S, Ventafridda V (1996) Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage 11(1):32–41

    Article  PubMed  CAS  Google Scholar 

  39. Vigano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME (2000) Clinical survival predictors in patients with advanced cancer. Arch Intern Med. 160(6):861–868

    Article  PubMed  CAS  Google Scholar 

  40. Vigano A, Dorgan M, Buckingham J, Bruera E, Suarez-Almazor ME (2000) Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med. 14(5):363–374

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This research was funded by Abbott Laboratories.

Author information

Authors and Affiliations

  1. Pharmaceutical Outcomes Research Program, University of Colorado School of Pharmacy, 4200 East Ninth Avenue, C238, Denver, CO, 80262, USA

    Patrick W. Sullivan

  2. Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Joel B. Nelson

  3. Abbott Laboratories, Abbott Park, IL, USA

    Parvez M. Mulani & Darryl Sleep

Authors
  1. Patrick W. Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joel B. Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Parvez M. Mulani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Darryl Sleep
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick W. Sullivan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sullivan, P.W., Nelson, J.B., Mulani, P.M. et al. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Qual Life Res 15, 1297–1306 (2006). https://doi.org/10.1007/s11136-006-0003-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-006-0003-2

Keywords

Search

Navigation